Business Description
TrivarX Ltd
ISIN : AU0000300196
Total Employee Number:
4Description
TrivarX Ltd is a health technology company developing AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions. Trivarx's clinical research has enabled the development of cutting-edge proprietary algorithms for spectral analyses of sleep architecture and heart rate variability. The Company has one operating segment, being the research, development and commercialisation of its software asaService product, and two geographical locations, being Australia and the United States.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 23.3 | |||||
Equity-to-Asset | 0.97 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.07 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 74.5 | |||||
3-Year EPS without NRI Growth Rate | 57.5 | |||||
3-Year FCF Growth Rate | 51.9 | |||||
3-Year Book Growth Rate | -27.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 36.55 | |||||
9-Day RSI | 38.93 | |||||
14-Day RSI | 41.9 | |||||
3-1 Month Momentum % | 64.71 | |||||
6-1 Month Momentum % | 55.56 | |||||
12-1 Month Momentum % | 250 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.45 | |||||
Quick Ratio | 5.45 | |||||
Cash Ratio | 5.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -65.1 | |||||
Shareholder Yield % | -25.05 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -13.29 | |||||
ROA % | -12.62 | |||||
ROIC % | -13.96 | |||||
3-Year ROIIC % | 33.49 | |||||
ROC (Joel Greenblatt) % | -1262.53 | |||||
ROCE % | -13.11 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.05 | |||||
Price-to-Tangible-Book | 10.5 | |||||
EV-to-EBIT | -9.96 | |||||
EV-to-Forward-EBIT | 117.51 | |||||
EV-to-EBITDA | -10.15 | |||||
EV-to-Forward-EBITDA | 39.17 | |||||
EV-to-Forward-Revenue | 3.71 | |||||
EV-to-FCF | -6.43 | |||||
Earnings Yield (Greenblatt) % | -10.04 | |||||
FCF Yield % | -13.41 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TrivarX Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.004 | ||
| Beta | 2.2016 | ||
| 3-Year Sharpe Ratio | 0.31 | ||
| 3-Year Sortino Ratio | 0.65 | ||
| Volatility % | 142.59 | ||
| 14-Day RSI | 41.9 | ||
| 14-Day ATR (A$) | 0.001691 | ||
| 20-Day SMA (A$) | 0.02375 | ||
| 12-1 Month Momentum % | 250 | ||
| 52-Week Range (A$) | 0.007 - 0.035 | ||
| Shares Outstanding (Mil) | 1,153.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TrivarX Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TrivarX Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-11-20 09:00 | In 146 days | ||
| Annual report for 2026 | 2026-09-29 | In 93 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-28 | In 61 days | ||
| Second quarter earnings results for 2026 | 2026-02-27 | 0.03 (+13.64%) | ||
| General meeting for 2025 | 2025-11-21 09:00 | 0.02 (+0.00%) | ||
| Annual report for 2025 | 2025-09-29 | 0.01 (-9.09%) | ||
| Fourth quarter earnings results for 2025 | 2025-08-28 | 0.01 (-5.26%) | ||
| Second quarter earnings results for 2025 | 2025-02-28 | 0.02 (-5.88%) | ||
| General meeting for 2024 | 2024-11-28 09:00 | 0.02 (+0.00%) | ||
| Annual report for 2024 | 2024-09-18 | 0.02 (+0.00%) |
Show
Entries
TrivarX Ltd Frequently Asked Questions
What is TrivarX Ltd(ASX:TRI)'s stock price today?
The current price of ASX:TRI is A$0.02. The 52 week high of ASX:TRI is A$0.04 and 52 week low is A$0.01.
When is next earnings date of TrivarX Ltd(ASX:TRI)?
The next earnings date of TrivarX Ltd(ASX:TRI) is 2026-08-28 Est..
Does TrivarX Ltd(ASX:TRI) pay dividends? If so, how much?
TrivarX Ltd(ASX:TRI) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Medibio Granted CE Mark Approval for MEBsleep | 2021-01-19 | ||
| Medibio Launches Personal Mental Health Measurement App for Apple Watch | 2018-05-09 |
Articles on TrivarX Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers